Literature DB >> 14726524

Trypsin IV, a novel agonist of protease-activated receptors 2 and 4.

Graeme S Cottrell1, Silvia Amadesi, Eileen F Grady, Nigel W Bunnett.   

Abstract

Certain serine proteases signal to cells by cleaving protease-activated receptors (PARs) and thereby regulate hemostasis, inflammation, pain and healing. However, in many tissues the proteases that activate PARs are unknown. Although pancreatic trypsin may be a physiological agonist of PAR(2) and PAR(4) in the small intestine and pancreas, these receptors are expressed by cells not normally exposed pancreatic trypsin. We investigated whether extrapancreatic forms of trypsin are PAR agonists. Epithelial cells lines from prostate, colon, and airway and human colonic mucosa expressed mRNA encoding PAR(2), trypsinogen IV, and enteropeptidase, which activates the zymogen. Immunoreactive trypsinogen IV was detected in vesicles in these cells. Trypsinogen IV was cloned from PC-3 cells and expressed in CHO cells, where it was also localized to cytoplasmic vesicles. We expressed trypsinogen IV with an N-terminal Igkappa signal peptide to direct constitutive secretion and allow enzymatic characterization. Treatment of conditioned medium with enteropeptidase reduced the apparent molecular mass of trypsinogen IV from 36 to 30 kDa and generated enzymatic activity, consistent with formation of trypsin IV. In contrast to pancreatic trypsin, trypsin IV was completely resistant to inhibition by polypeptide inhibitors. Exposure of cell lines expressing PAR(2) and PAR(4) to trypsin IV increased [Ca(2+)](i) and strongly desensitized cells to PAR agonists, whereas there were no responses in cells lacking these receptors. Thus, trypsin IV is a potential agonist of PAR(2) and PAR(4) in epithelial tissues where its resistance to endogenous trypsin inhibitors may permit prolonged signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726524     DOI: 10.1074/jbc.M312090200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 2.  Proteases, cystic fibrosis and the epithelial sodium channel (ENaC).

Authors:  P H Thibodeau; M B Butterworth
Journal:  Cell Tissue Res       Date:  2012-05-22       Impact factor: 5.249

3.  Neutrophil Elastase Activates Protease-activated Receptor-2 (PAR2) and Transient Receptor Potential Vanilloid 4 (TRPV4) to Cause Inflammation and Pain.

Authors:  Peishen Zhao; TinaMarie Lieu; Nicholas Barlow; Silvia Sostegni; Silke Haerteis; Christoph Korbmacher; Wolfgang Liedtke; Nestor N Jimenez-Vargas; Stephen J Vanner; Nigel W Bunnett
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

4.  Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Authors:  Thomas Gobbetti; Nicolas Cenac; Jean-Paul Motta; Corinne Rolland; Laurence Martin; Patricia Andrade-Gordon; Martin Steinhoff; Elisabetta Barocelli; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

5.  Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains.

Authors:  Edit Szepessy; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2006-06-05       Impact factor: 5.542

Review 6.  Protease-activated receptors: regulation of neuronal function.

Authors:  Toshiyuki Saito; Nigel W Bunnett
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

7.  Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis.

Authors:  Graeme S Cottrell; Silvia Amadesi; Stella Pikios; Eric Camerer; J Adam Willardsen; Brett R Murphy; George H Caughey; Paul J Wolters; Shaun R Coughlin; Anders Peterson; Wolfgang Knecht; Charalabos Pothoulakis; Nigel W Bunnett; Eileen F Grady
Journal:  Gastroenterology       Date:  2007-04-13       Impact factor: 22.682

8.  Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Authors:  Steeve Houle; Martin D Papez; Mara Ferazzini; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

9.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

10.  Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice.

Authors:  R Costa; D M Marotta; M N Manjavachi; E S Fernandes; J F Lima-Garcia; A F Paszcuk; N L M Quintão; L Juliano; S D Brain; J B Calixto
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.